Over the past 20 years, Endocrine Metabolic Immune Disorders-Drug Targets (EMIDDT)
journal has been covering a broad field of intertwined topics related to pathogenesis, diagnosis,
and therapy of endocrine, metabolic, and immune diseases. At first, the journal publications
were restricted to reviews only and, then, original article submissions have also been accepted.
EMIDDT represents as a successful journal in continuous expansion with 10 issues in 2020 and a
current impact factor (IF) equal to 1.973. Moreover, since 2019, EMIDDT is the official journal of
the Italian AME (Associazione Medici Endocrinologi), also linked to the American Association of
Endocrinologists. Such a connection has given more impetus to the journal in terms of additional
higher-quality submissions. In order to celebrate the 20th anniversary of EMIDDT, the content of
some original representative articles published by the journal in the past and current years will be illustrated
with special emphasis on cellular and molecular bases of drug targeting.
